Nasdaq

Lilly's Emgality Gets FDA Approval for Cluster Headache

Eli Lilly and Company LLY announced that the FDA has granted approval to its CGRP antibody, Emgality injection (300 mg) for the preventive treatment of episodic cluster headache in adult patients.
Nasdaq

Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments

INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...
Business Insider

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...
Business Insider

Emgality® (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache

The first and only anti-CGRP treatment with dual indications TORONTO, Feb. 25, 2021 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce that Emgality® (galcanezumab) is now indicated ...
Monthly Prescribing Reference

Emgality sBLA Gets Priority Review for Preventive Treatment of Episodic Cluster Headache

The supplemental New Drug Application (sNDA) for Emgality (galcanezumab-gnlm; Lilly) has been granted Priority Review by the Food and Drug Administration (FDA) for the preventive treatment of episodic ...